Showing results (311-320 of 547) with videos related to

Sort By:
Pageof 55
Bulletin De La Societe De Pathologie Exotique (1990)|July 30, 2005
[HIV seroprevalence among tuberculosis patients in Nkembo Hospital, Libreville, Gabon. Short note]D Nkoghe, M Toung Mve, S Nnegue, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 3, 2016
CHOP Chemotherapy Followed by Tositumomab and Iodine-131 Tositumomab for Previously Untreated Diffuse Large B-cell LymphomaJohn P Leonard, Stephanie A Gregory, Hedy Smith, et al.
Palliative & Supportive Care|June 17, 2022
Unmet mental health needs in patients with advanced B-cell lymphomasChrystal Marte, Login S George, Sarah C Rutherford, et al.
Annals of the Royal College of Surgeons of England|April 26, 2001
Neo-adjuvant therapy improves resectability rates for colorectal liver metastasesA Shankar, P Leonard, A J Renaut, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 17, 1996
Thrombopoietic potential and serial repopulating ability of murine hematopoietic stem cells constitutively expressing interleukin 11R G Hawley, T S Hawley, A Z Fong, et al.
Blood|August 15, 2002
Efficacious immunomodulatory activity of the chemokine stromal cell-derived factor 1 (SDF-1): local secretion of SDF-1 at the tumor site serves as T-cell chemoattractant and mediates T-cell-dependent antitumor responsesKyriaki Dunussi-Joannopoulos, Krystyna Zuberek, Kathlene Runyon, et al.
Cancer|October 15, 2008
Durable complete responses from therapy with combined epratuzumab and rituximab: final results from an international multicenter, phase 2 study in recurrent, indolent, non-Hodgkin lymphomaJohn P Leonard, Stephen J Schuster, Christos Emmanouilides, et al.
Leukemia & Lymphoma|January 24, 2012
Bortezomib in combination with rituximab, dexamethasone, ifosfamide, cisplatin and etoposide chemoimmunotherapy in patients with relapsed and primary refractory diffuse large B-cell lymphomaRebecca L Elstrom, Biree Andemariam, Peter Martin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 24, 2012
Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsivenessM S Czuczman, J P Leonard, S Jung, et al.
Cancer|March 15, 2008
Prednisone, etoposide, procarbazine, and cyclophosphamide (PEP-C) oral combination chemotherapy regimen for recurring/refractory lymphoma: low-dose metronomic, multidrug therapyMorton Coleman, Peter Martin, Jia Ruan, et al.
Pageof 55